NOVO-B:CPH
Novo Nordisk A/S
DKK 253.50
arrow_upward
+0.50%(+1.25) 1D
Sep 29, 1:34:49 PM GMT+2 · DKK
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NOVO-B...
Open
DKK 252.50
High
DKK 254.80
Low
DKK 251.50
Mkt. cap
857.70B
Avg. vol.
4.78M
Volume
1.34M
52-wk high
DKK 409.95
52-wk low
DKK 224.25
Shares outstanding
3.39B
No. of employees
67K
Open
DKK 252.50
High
DKK 254.80
Low
DKK 251.50
Mkt. cap
857.70B
Avg. vol.
4.78M
Volume
1.34M
52-wk high
DKK 409.95
52-wk low
DKK 224.25
Shares outstanding
3.39B
No. of employees
67K
News stories
From web sources and news partners
The Cryptonomist
·
1 hour ago
Novo Nordisk Stock Analysis: Bearish Trend Meets Oversold Bounce
Euronext Markets: Real-time Stock Market Data | live
·
1 hour ago
Novo to pay up to $2.6 billion to China's Hengrui for rights to weight-loss pill
Investing.com South Africa
·
4 hours ago
Hengrui Pharma shares rise as Novo Nordisk signs $2.6 billion drug deal By Investing.com
TipRanks
·
19 hours ago
Novo Nordisk Details Progress of DKK 15 Billion Share Buyback Programme
Profile
Novo is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds approximately 28.1% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. Novo's market capitalization exceeded the GDP of Denmark's domestic economy in 2023, and it is the highest valued company in Europe. Wikipedia
About Novo Nordisk A/S
CEOMaziar Mike Doustdar
Employees66.7K
FoundedDec 21, 1923
HeadquartersBagsværd, Capital Region of Denmark, Denmark
SectorPharmaceutical industry
Websitenovonordisk.com